FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($1.93) for the year, up from their previous forecast of ($1.97). Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.96) per share.

ZVRA has been the topic of a number of other research reports. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Maxim Group increased their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. JMP Securities began coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 price objective for the company. Roth Mkm raised their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Finally, Guggenheim began coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $20.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $21.57.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA traded down $0.42 during mid-day trading on Friday, reaching $8.11. 565,209 shares of the company's stock were exchanged, compared to its average volume of 473,235. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The business's fifty day simple moving average is $8.79 and its two-hundred day simple moving average is $7.59. The firm has a market capitalization of $432.88 million, a PE ratio of -4.12 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the previous year, the business earned ($0.40) EPS.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC lifted its holdings in shares of Zevra Therapeutics by 8.1% in the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company's stock worth $159,000 after acquiring an additional 1,717 shares during the last quarter. City State Bank lifted its stake in Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after purchasing an additional 2,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. International Assets Investment Management LLC boosted its position in Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock valued at $48,000 after buying an additional 5,940 shares in the last quarter. Finally, IFG Advisors LLC grew its stake in shares of Zevra Therapeutics by 41.2% during the third quarter. IFG Advisors LLC now owns 26,400 shares of the company's stock worth $183,000 after buying an additional 7,700 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.